David S. Mathiesen

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

T. Vilsbøll, F. Knop, J. Bagger, 2021, Frontiers in Endocrinology.

Long-acting amylin analogues for the management of obesity

F. Knop, J. Bagger, David S. Mathiesen, 2022, Current opinion in endocrinology, diabetes, and obesity.

Dose‐dependent efficacy of the glucose‐dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3‐30)NH2 on GIP actions in humans

J. Holst, M. Rosenkilde, M. Christensen, 2020, Diabetes, obesity & metabolism.

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review

M. Christensen, T. Vilsbøll, F. Knop, 2019, International journal of molecular sciences.

Protocol for a 30-day randomised, parallel-group, non-inferiority, controlled trial investigating the effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19: the RASCOVID-19 trial

M. Christensen, T. Vilsbøll, F. Knop, 2022, BMJ Open.

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

T. Hansen, J. Holst, A. Jonsson, 2020, Endocrine connections.